首页 › 基金 › Frazier Life Sciences Management, L.P. › DSGN
Frazier Life Sciences Management, L.P. 对 DSGN 的持仓历史
DESIGN THERAPEUTICS INC · 医疗保健
Frazier Life Sciences Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 DSGN(DESIGN THERAPEUTICS INC)1,809,854 股,市值约 US$26.2M,约占其申报组合的 0.57%,在其申报持仓中市值排名第 28 位。 Frazier Life Sciences Management, L.P. 最近 9 个申报季度中有 8 个季度披露了 DSGN 持仓,最早可追溯至 Q2 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Frazier Life Sciences Management, L.P. 对 DSGN 的持仓演变
Frazier Life Sciences Management, L.P. 于 Q2 2024 首次披露 DSGN 持仓:1,195,179 股(约 US$4.0M)。 该持仓在 Q2 2026 达到峰值 1,809,854 股,市值约 US$26.2M。 在 8 次申报中,Frazier Life Sciences Management, L.P. 2 次增持、1 次减持、3 次保持不变。 最近一期申报(Q2 2026)显示持股 1,809,854 股、市值约 US$26.2M。 持仓曾出现大幅变动:Q3 2024 增持约 58% (随后一个季度股价上涨 15%)、Q4 2025 减持约 73% (随后一个季度股价上涨 13%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2024 | 1.20M | $4.00M | 新进 |
| Q3 2024 | 1.89M | $10.18M | 增持 |
| Q4 2024 | 1.95M | $12.05M | 增持 |
| Q1 2025 | 1.95M | $7.54M | 持有 |
| Q2 2025 | 1.95M | $6.58M | 持有 |
| Q3 2025 | 1.95M | $14.71M | 持有 |
| Q4 2025 | 521.00K | $4.89M | 减持 |
| Q2 2026 | 1.81M | $26.19M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DSGN 与 13F 数据
DSGN(DESIGN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 47 只申报持有 DSGN,申报仓位最大的包括:SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DSGN 的基金
- SR ONE CAPITAL MANAGEMENT, LP 6.53M 股 · $94.44M · Q2 2026
- Logos Global Management LP 3.00M 股 · $43.41M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M 股 · $38.76M · Q2 2026
- Trails Edge Capital Partners, LP 2.00M 股 · $28.96M · Q2 2026
- Vivo Capital, LLC 1.61M 股 · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M 股 · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K 股 · $12.52M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 282.56K 股 · $4.09M · Q2 2026
- KVP Capital Advisors, LP 185.00K 股 · $2.68M · Q2 2026
- Elmind Capital, LP 107.90K 股 · $1.56M · Q2 2026
更多关于 Frazier Life Sciences Management, L.P.
常见问题
How long has Frazier Life Sciences Management, L.P. held DSGN?
Frazier Life Sciences Management, L.P. has disclosed DSGN holdings in 8 of the last 9 reported quarters, going back to Q2 2024.
What is Frazier Life Sciences Management, L.P.'s current position in DSGN?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.81M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $26.19M, representing 0.57% of its reported portfolio and ranking #28.
Has Frazier Life Sciences Management, L.P. been buying or selling DSGN?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. newly opened its position in DSGN. The position peaked in Q2 2026 at 1.81M shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BAKER BROS. ADVISORS LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.